MARKET

CAPR

CAPR

Capricor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.800
-0.020
-1.10%
Closed 16:23 11/18 EST
OPEN
1.920
PREV CLOSE
1.820
HIGH
1.925
LOW
1.780
VOLUME
19.47K
TURNOVER
--
52 WEEK HIGH
9.45
52 WEEK LOW
1.709
MARKET CAP
7.64M
P/E (TTM)
-0.4789
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CAPR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CAPR News

  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.4d ago
  • Solid Bio down 59% premarket on another clinical hold on DMD gene therapy
  • Seeking Alpha - Article.6d ago
  • Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/09 02:24
  • Capricor Therapeutics EPS beats by $0.25, misses on revenue
  • seekingalpha.11/08 02:31

More

Industry

Biotechnology & Medical Research
+0.31%
Pharmaceuticals & Medical Research
+0.13%

Hot Stocks

Name
Price
%Change

About CAPR

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
More

Webull offers Capricor Therapeutics Inc (CAPR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.